Bicuspid Aortic Valve Replacement: Evaluation of Transcatheter Versus Surgery-Pilot Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-31

Study Completion Date

2037-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study protocol is a randomized trial of standard of care therapies for severe aortic stenosis (AS) in patients with a bicuspid aortic valve (BAV). Namely, the therapies to which patients will be randomized will be transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), in patients deemed clinically suitable for both following heart team review.

The purpose of this study is to compare the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) versus Surgical Aortic Valve Replacement (SAVR) for treating patients with severe aortic stenosis (AS) who have a congenital bicuspid aortic valve (BAV) anatomy. Patients with BAV anatomy have been under-represented in previous trials and this study might provide important information to help guide future treatment options.

The study patients will be followed with standard of care procedures for 10 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bicuspid Aortic Valve Stenosis Transcatheter Aortic Valve Replacement Registry

NCT03836521

Bicuspid Aortic Valve

RECRUITING

The Bicuspid Aortic Stenosis Following Transcatheter Aortic Valve Replacement Registry

NCT02394184

Aortic Valve Stenosis Cardiovascular Diseases Heart Valve Diseases +1 more

COMPLETED

The Safety and Effectiveness of Transcatheter Aortic Valve Raplacemet in Intermediate Risk Patients With Bicuspid Aortic Stenosis

NCT03163329

Aortic Valve Disease

UNKNOWN PHASE2

Randomized Trial of TAVI vs. SAVR in Patients With Severe Aortic Valve Stenosis at Low to Intermediate Risk of Mortality

NCT03112980

Aortic Valve Stenosis

ACTIVE_NOT_RECRUITING NA

Bicuspid Valve Aortopathy Feasibility Study

NCT01920815

Bicuspid Aortic Valve

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Stenosis Bicuspid Aortic Valve

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

transcatheter aortic valve replacement (TAVR)

50% of patients will be treated with standard TAVR procedure and followed up for 10 years

Group Type ACTIVE_COMPARATOR

transcatheter aortic valve replacement (TAVR)

Intervention Type PROCEDURE

percutaneous transcatheter aortic valve replacement

surgical aortic valve replacement (SAVR)

50% of patients will be treated with standard SAVR procedure and followed up for 10 years

Group Type ACTIVE_COMPARATOR

surgical aortic valve replacement (SAVR)

Intervention Type PROCEDURE

surgical aortic valve replacement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transcatheter aortic valve replacement (TAVR)

percutaneous transcatheter aortic valve replacement

Intervention Type PROCEDURE

surgical aortic valve replacement (SAVR)

surgical aortic valve replacement

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged \> 50 years of age
* Site-determined severe AS deemed necessary for treatment with SAVR or TAVR
* Gated contrast CT available and suitable for core laboratory analysis
* BAV anatomy confirmed by CT core laboratory analysis

Exclusion Criteria

* Recent cardiovascular intervention within the prior 30 days.
* Presence of an existing TAVR or SAVR device
* Pregnancy or lactation
* Extreme or prohibitive TAVR or SAVR risk, determined by site or committee Active enrollment in another investigational study
* Disproportionate TAVR vs SAVR risk, as determined by treating site or committee
* Associated aortopathy (AA≥ 45 mm by maximal cross-sectional dimension, as confirmed by CT core laboratory analysis, or AA\<45 mm but site plan for surgery of the aorta in the event of randomization to surgery
* Site plan for treatment of concomitant non-coronary cardiovascular disease in the event of randomization to surgery (for instance, concomitant valve surgery, septal defect or coarctation repair, aorta or root replacement or repair)
* In the presence of coronary artery disease deemed necessary for revascularization in the event of randomization to SAVR or TAVR, Syntax score ≥ 32 or deemed unsuitable for PCI, or deemed unsuitable for coronary artery bypass grafting (CABG).

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No